Patents Assigned to Protiva Biotherapeutics Inc.
-
Patent number: 9364435Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: August 18, 2014Date of Patent: June 14, 2016Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20160151284Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: July 22, 2014Publication date: June 2, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Patent number: 9352042Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.Type: GrantFiled: February 22, 2013Date of Patent: May 31, 2016Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James Heyes, Mark Wood, Alan Martin
-
Publication number: 20160076035Abstract: The present invention provides compositions comprising siRNA molecules that target Marburg virus (MARV) gene expression, lipid particles comprising one or more (e.g., a combination) of the siRNA molecules, and methods of delivering and/or administering the lipid particles, for the purposes of treating MARV infection.Type: ApplicationFiled: August 21, 2015Publication date: March 17, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Raul J. Ursic Bedoya, Ian MacLachlan, Marjorie Ann Robbins
-
Patent number: 9222086Abstract: The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.Type: GrantFiled: September 23, 2010Date of Patent: December 29, 2015Assignees: PROTIVA BIOTHERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Adam Judge, Yun-Han Lee, Ian MacLachlan, Snorri S. Thorgeirsson
-
Patent number: 9181545Abstract: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.Type: GrantFiled: August 6, 2010Date of Patent: November 10, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lorne R. Palmer, James Heyes
-
Publication number: 20150315584Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).Type: ApplicationFiled: April 1, 2015Publication date: November 5, 2015Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Marcia MacDonald, Amy C.H. Lee, lan MacLachlan
-
Patent number: 9126966Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: August 30, 2012Date of Patent: September 8, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Alan Martin, James Heyes, Mark Wood
-
Patent number: 9074208Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: July 26, 2013Date of Patent: July 7, 2015Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Ian MacLachlan, Adam Judge
-
Patent number: 9035039Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).Type: GrantFiled: December 21, 2012Date of Patent: May 19, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ammen P. Dhillon, Amy C. H. Lee, Ian MacLachlan
-
Patent number: 9023820Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA that target apolipoprotein C-III (APOC3) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for the treatment of lipid diseases or disorders such as atherosclerosis or a dyslipidemia such as hypertriglyceridemia or hypercholesterolemia).Type: GrantFiled: January 26, 2010Date of Patent: May 5, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Marcia MacDonald, Amy C. H. Lee, Ian MacLachlan
-
Patent number: 9018187Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid in vivo. The compositions of the present invention are highly potent, thereby allowing effective know-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: October 1, 2013Date of Patent: April 28, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Lorne Palmer, Magdalena Maslowski, Ian MacLachlan
-
Patent number: 9006417Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: June 30, 2011Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 9005654Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid, is included in one of the buffer solution or the lipid solution. Upon mixing a liposome encapsulating the therapeutic product is substantially instantaneously formed. Thereafter the liposome solution formed is immediately diluted with buffer solution to enhance homogeneity and maintain small particle size.Type: GrantFiled: July 27, 2006Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Edward Yaworski, Kieu Lam
-
Patent number: 9006191Abstract: The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties.Type: GrantFiled: December 23, 2008Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Patent number: 8999950Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).Type: GrantFiled: October 4, 2012Date of Patent: April 7, 2015Assignee: Protiva Biotherapeutics Inc.Inventors: Ian MacLachlan, Amy C. H. Lee
-
Patent number: 8936942Abstract: The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.Type: GrantFiled: August 6, 2010Date of Patent: January 20, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Ellen Grace Ambegia
-
Patent number: 8865675Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: May 12, 2011Date of Patent: October 21, 2014Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin, Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ian MacLachlan
-
Publication number: 20140288146Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: April 25, 2013Publication date: September 25, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Publication number: 20140248338Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target aldehyde dehydrogenase (ALDH) gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating alcoholism in humans).Type: ApplicationFiled: October 4, 2012Publication date: September 4, 2014Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Amy C.H. Lee